Today: 19 April 2026
Subscribe
Browse Category

LSE:VOD 24 February 2025

Internet Access in Iraq

Internet Access in Iraq

Iraq’s Ministry of Communications controls the national fiber backbone and leases bandwidth to private ISPs at about $50 per 1 Mbps. By early 2024, internet users reached 36.2 million, or nearly 79% of the population. Vodafone received a 5G license in November 2024. Authorities have imposed internet shutdowns during protests, including a 263-hour blackout in 2019.
24 February 2025
···
Internet Access in Ukraine: Overview

Internet Access in Ukraine: Overview

Over 4,200 ISPs operated in Ukraine as of August 2024, with Kyivstar holding 19% market share. Starlink received an operator license in April 2022 and had about 42,000 terminals by 2023. Median fixed broadband speed was 74–84 Mbps; mobile, 24–43 Mbps. Around 29.6 million Ukrainians used the internet in 2023, or 79% of the population.
24 February 2025
···
1 … 3 4 5

Stock Market Today

  • Brown-Forman (BF.B) Faces Valuation Debate After Strong Short-Term Rally
    April 18, 2026, 9:26 PM EDT. Brown-Forman's (BF.B) stock surged about 27% in one month, reversing last year's roughly 11% decline. The recent sharp rebound contrasts with a weaker long-term trend, highlighting momentum shifts. Despite shares trading near analyst price targets at $29.15, fair value estimates diverge widely. Simply Wall St's discounted cash flow (DCF) model values Brown-Forman at $37.78, suggesting undervaluation, while another model pegs fair value at $21.00, indicating the stock is roughly 39% overvalued. The gap reflects differing views on declining global alcohol consumption due to rising health awareness, which could pressure Brown-Forman's revenue growth. However, premium spirits and emerging market demand might offset some risks. Investors face critical decisions amid mixed signals, weighing whether current prices embed growth prospects or overestimate future earnings.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Go toTop